After chemotherapy failed and his survival odds fell to just 10%, an 8 year old

A closer look at After chemotherapy failed and his survival odds fell to just 10%, an 8 year old

A real patient story about a child with Burkitt’s lymphoma

This UVA Health page tells the story of Joshua, an 8-year-old whose primary refractory Burkitt’s lymphoma did not respond to four rounds of chemotherapy. It describes how his family researched options, brought a published New England Journal of Medicine article to his pediatric oncologist Daniel “Trey” Lee, MD, and how the care team pursued new immunotherapy approaches.

What you can learn and what happened on the site

The article explains the sequence of Joshua’s care: parent-led research, development of a pediatric dosing protocol for an immunotherapy referenced in the literature, improvement after the new immunotherapy, a relapse shown on PET scan, preparation for CAR T-cell therapy, use of additional medications to improve CAR T effectiveness, and finally a bone marrow transplant from his 2-year-old brother Caleb. It also notes the treatment team’s emphasis on timing for T-cell collection and that the family received psychosocial and educational support during hospitalization.

Who will find this useful

Families and caregivers of children with aggressive or treatment-resistant cancers may find the account informative about one center’s pathway for trying novel immunotherapies and CAR T when standard chemotherapy fails. Clinicians and patient advocates interested in real-world examples of parent involvement in care decisions may also find the narrative useful. The piece also highlights the role of multidisciplinary support during prolonged treatment.

Questions people ask about After chemotherapy failed and his survival odds fell to just 10%, an 8 year old

Does the page describe an outcome for the child?

Yes; after the combined treatments and a bone marrow transplant from his brother, Joshua’s cancer was gone 59 days after the CAR T approach and he proceeded to transplant.

Does the article explain how the new treatments were chosen?

It says the family found a New England Journal of Medicine article, the physician consulted colleagues, developed a pediatric dosing protocol, and prepared CAR T as a back-up based on tumor analysis.

Will I find technical treatment protocols or costs on this page?

No; the article is a patient story describing the clinical decisions and support around Joshua’s care, not detailed protocols or pricing information.

After chemotherapy failed and his survival odds fell to just 10%, an 8 year old was shared on NexURLs by Nexis on October 31, 2026, in Health & Fitness.